Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile.
about
A Review of Experimental and Off-Label Therapies for Clostridium difficile InfectionCurrent state of a dual behaviour of antimicrobial peptides-Therapeutic agents and promising delivery vectors.Targeted delivery of geranylgeranylacetone to mitochondria by triphenylphosphonium modified nanoparticles: a promising strategy to prevent aminoglycoside-induced hearing loss.Advances in therapeutic bacterial antisense biotechnology.Cationic amphiphilic bolaamphiphile-based delivery of antisense oligonucleotides provides a potentially microbiome sparing treatment for C. difficile.
P2860
Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Bolaamphiphile-based nanocompl ...... ent for Clostridium difficile.
@en
type
label
Bolaamphiphile-based nanocompl ...... ent for Clostridium difficile.
@en
prefLabel
Bolaamphiphile-based nanocompl ...... ent for Clostridium difficile.
@en
P2093
P2860
P356
P1476
Bolaamphiphile-based nanocompl ...... ment for Clostridium difficile
@en
P2093
David B Stewart
Diana Guzman-Villanueva
Jacek Krzeminski
Volkmar Weissig
P2860
P304
P356
10.2147/IJN.S109600
P407
P577
2016-08-01T00:00:00Z